View Older Stories View More Recent Stories
-
Valeant (VRX) Had 95 New Price Increases, Wells Fargo's Maris Notes
-
Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal
-
Trump presidency could prove a salve for pharma merger deals
-
Valeant Pharma (VRX) EBITDA Was North of $1B, Which Was Better than Feared - Evecore ISI Raffat
-
Valeant (VRX) 3Q Earnings Preview: Underlying RX Trends Remain Weak - Wells Fargo
-
Imprimis Pharma (IMMY) Announces Lower-Cost Option to Valeant's (VRX) Lead Poisoning Treatment
-
Drug Stocks on Watch as Bipartisian Bill Expected on Capping Price Increases
-
Mylan (MYL), Valeant (VRX), Related Stocks Pressured Following Market Open
-
Mylan to launch generic EpiPen at half the price of original
-
PCMA: 'It Was Mistake for Mylan (MYL) to Adopt Pricing Strategy Used Unsuccessfully by Valeant (VRX), Turing'
-
Valeant amends credit facility for second time in six months
-
Valeant stock falls as report of criminal probe adds to woes
-
Valeant looks to sell billions in assets to cut debt, stock soars
-
Valeant's former CEO to receive $9 million severance payment, other fees
-
Valeant CEO Papa plans to lower debt by more than $1.5 billion in 2016
-
Valeant gets notice of default from bondholders
-
Activist investor heavyweights form new lobbying arm
-
Wells Fargo Trims Valuation Range on Valeant (VRX) Following New Exec Bonus Structure
-
Regulatory filings show which Valeant investors exited in first quarter
-
Valeant Pharma (VRX) Expands Discounts For Nitropress And Isuprel
-
Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel
-
S&P Lifts Outlook on Valeant Pharma (VRX) to Positive; Sees Lower Risk of Near-Term Default
-
Valeant annual report reveals new issues, company overhauls board
-
Ackman, Valeant pledge reforms after spiking drug prices
-
Valeant names Papa CEO after he resigns from Perrigo
-
Valeant gets additional notices of default from bondholders
-
Drugmaker Valeant's bondholders intend to call default
-
Top Democrat, in letter, blasts Valeant CEO for lack of cooperation
-
Rep. Cummings Sends Letter to Valeant (VRX) CEO Pearson; Says Information Withheld from Congress
-
Valeant gets extra month to file annual report
-
Regulator orders drugmaker Valeant management to cease trading
-
Senate's request for info from Ackman related to Valeant: source
-
Drugmaker Valeant CEO leaving as investor Ackman joins board
-
Exclusive: Valeant lenders to prepare tough demands for default talks – sources
-
Drugmaker Valeant faces debt default risk; shares plunge 50 percent
-
Citron's Left Sees Valeant Pharma (VRX) Stock as 'Uninvestible'; Has Been Contacted by SEC
-
Deutsche Bank Suspends Coverage on Valeant Pharma (VRX)
-
Valeant CEO Pearson to return effective immediately, results delayed
-
SIRF Questions Valeant Pharma (VRX) Wellbutrin XL Revenue
-
CVS says 2015 drug spending grew 5 percent, far less than in 2014
-
Smirking Shkreli refuses lawmakers' questions, calls them 'imbeciles'
-
House Memo on Valeant (VRX) 'Incrementally Negative' - BMO Capital
-
Did Price or Volume Drive Valeant Pharma (VRX) Growth?; Evercore ISI's Raffat Digs In
-
Valeant defends price hikes after Clinton remarks; shares jump
-
Express Scripts (ESRX) Aims to Clamp Down on High Drug Prices; Excludes Valeant's (VRX) Glumetza from Formulary
-
Clinton targets Valeant price hikes in campaign appearance
-
Valeant's Pearson says timing of return uncertain
-
Major drugmakers push back in U.S. price debate
-
Valeant Pharma's (VRX) Interim CEO Schiller to Refrain From Sharp Price Hikes
-
Valeant to appoint interim CEO as Pearson remains hospitalized: source
